強直性脊椎炎 | Ankylosing Spondylitis

強直性脊柱炎

强直性脊柱炎（AS）是一種慢性免疫介導的炎症性關節炎，被稱為脊柱關節炎（SpA）組。它通常發生在男性的第三個十年的生活和影響主要是軸向骨骼和骶髂關節。儘管最古老的描述可以追溯到加倫時代，但直到19世紀，根據弗拉基米爾·別赫捷列夫、阿道夫·斯特呂佩爾和皮埃爾·瑪麗的報告，才能够準確地診斷出這種疾病。已知HLA-B27等位基因與疾病1有很强的關聯；然而，其他基因在疾病的發展中也起了作用。多種炎症途徑的發現導致了生物治療時代的到來，這意味著AS治療和預後的一場革命。(1)

酶單獨使用對鼻竇炎和支氣管炎有療效(2)
動脈粥樣硬化有療效(2)
腕管綜合征有療效(2)
類風濕性關節炎和其他自身免疫性疾病有療效(2)
Punicalagin 有望成為治療强直性脊柱炎的有效候選化合物(3)

Ankylosing spondylitis

Ankylosing spondylitis (AS) is a chronic immune-mediated inflammatory arthritis included in the so-called group of spondyloarthritis (SpA). It typically develops in males in their third decade of life and affects mainly the axial skeleton and the sacroiliac joints. Although the oldest descriptions date from the time of Galen, it was not until the 19th century that the disease could be accurately diagnosed on the basis of reports by Vladimir Bekhterev, Adolph Strümpell, and Pierre Marie. The HLA-B27 allele is known to have a strong association with the disease 1; however, other genes play a part in its development. The discovery of several inflammatory pathways led to the era of the biologic therapies, which meant a revolution in the treatment and prognosis of AS. (1)

Refs:

Garcia-Montoya L, Gul H, Emery P. Recent advances in ankylosing spondylitis: understanding the disease and management. F1000Res. 2018;7:F1000 Faculty Rev-1512. Published 2018 Sep 21. doi:10.12688/f1000research.14956.1
Manju Tiwari*. The role of serratiopeptidase in the resolution of inflammation. Asian J Pharm Sci. 2017 May; 12(3): 209–215. Published online 2017 Feb 1. doi: 10.1016/j.ajps.2017.01.003. PMCID: PMC7032259. PMID: 32104332
Xinzhe Feng, Qinyuan Yang, Chen Wang, Wenwen Tong, Weidong Xu, "Punicalagin Exerts Protective Effects against Ankylosing Spondylitis by Regulating NF-κB-TH17/JAK2/STAT3 Signaling and Oxidative Stress", BioMed Research International, vol. 2020, Article ID 4918239, 12 pages, 2020. https://doi.org/10.1155/2020/4918239